Seagen Announces TUKYSA® (Tucatinib) in Combination with Trastuzumab Granted Priority Review by FDA for Previously Treated HER2-Positive Metastatic Colorectal Cancer

Seagen, Inc. announced that the US FDA has accepted for Priority Review the supplemental New Drug Application seeking accelerated approval for TUKYSA® in combination with trastuzumab for adult patients with HER2-positive colorectal cancer.
[Seagen, Inc.]
Press Release